Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
February 06, 2023 08:30 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven...
Connect Biopharma Provides Business and Clinical Development Program Update
December 30, 2022 07:30 ET
|
Connect Biopharma Holdings Limited
Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of...
Connect Biopharma to Present at the San Francisco Biotech Showcase in January
December 19, 2022 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage...
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
December 02, 2022 17:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage...
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
October 27, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven...
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
October 04, 2022 08:56 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note that in...
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
October 04, 2022 07:00 ET
|
Connect Biopharma Holdings Limited
All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe ADSafety and tolerability results for CBP-201 consistent with targeting...
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
October 03, 2022 16:10 ET
|
Connect Biopharma Holdings Limited
Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,tomorrow, Tuesday, October 4 SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma...
Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update
September 13, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 – – Company to Host Conference Call Today at 4:30 p.m. ET – ...
Connect Biopharma to Report First Half 2022 Financial Results on September 13
September 01, 2022 08:00 ET
|
Connect Biopharma Holdings Limited
Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB)...